| Literature DB >> 27147480 |
Sam Massa1,2, Niravkumar Vikani2, Cecilia Betti3, Steven Ballet3, Saskia Vanderhaegen4,5, Jan Steyaert4,5, Benedicte Descamps6, Christian Vanhove6, Anton Bunschoten7, Fijs W B van Leeuwen7, Sophie Hernot1, Vicky Caveliers1,8, Tony Lahoutte1,8, Serge Muyldermans2, Catarina Xavier9, Nick Devoogdt10,11.
Abstract
A generic site-specific conjugation method that generates a homogeneous product is of utmost importance in tracer development for molecular imaging and therapy. We explored the protein-ligation capacity of the enzyme Sortase A to label camelid single-domain antibody-fragments, also known as nanobodies. The versatility of the approach was demonstrated by conjugating independently three different imaging probes: the chelating agents CHX-A"-DTPA and NOTA for single-photon emission computed tomography (SPECT) with indium-111 and positron emission tomography (PET) with gallium-68, respectively, and the fluorescent dye Cy5 for fluorescence reflectance imaging (FRI). After a straightforward purification process, homogeneous single-conjugated tracer populations were obtained in high yield (30-50%). The enzymatic conjugation did not affect the affinity of the tracers, nor the radiolabeling efficiency or spectral characteristics. In vivo, the tracers enabled the visualization of human epidermal growth factor receptor 2 (HER2) expressing BT474M1-tumors with high contrast and specificity as soon as 1 h post injection in all three imaging modalities. These data demonstrate Sortase A-mediated conjugation as a valuable strategy for the development of site-specifically labeled camelid single-domain antibody-fragments for use in multiple molecular imaging modalities.Entities:
Keywords: HER2; Sortase A; chemoenzymatic ligation; multimodal; nanobody; sdAb; site-specific conjugation
Mesh:
Substances:
Year: 2016 PMID: 27147480 DOI: 10.1002/cmmi.1696
Source DB: PubMed Journal: Contrast Media Mol Imaging ISSN: 1555-4309 Impact factor: 3.161